IMCR
Immunocore Holdings plcstockNASDAQADR
immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body's own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host's own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 30.48 | 2026-11-12 | -9.63% | 1.452 |
| 1M | 29.84 | 2026-10-19 | -7.71% | 0.947 |
| 3M | 36.86 | 2026-08-19 | -25.29% | 0.863 |
| 6M | 28.93 | 2026-05-19 | -4.80% | 0.538 |
| 1Y | 38.65 | 2025-11-19 | -28.75% | 0.654 |
| 2Y | 32.56 | 2024-11-19 | -15.42% | — |
| 5Y | 38.10 | 2021-11-19 | -27.72% | 0.777 |
Immunocore Holdings plc (NASDAQ:IMCR) stock price today is $27.54, and today's volume is 296,510. IMCR is down 0.971% today. The 30 day average volume is 511,083. IMCR market cap is $1.42B with 51.68M shares outstanding.